Valuation: Orexo AB

Market Cap 85Cr 8.81Cr 7.71Cr 7.1Cr 6.59Cr 13Cr 840.01Cr 13Cr 33Cr 412.33Cr 33Cr 32Cr 1.43TCr P/E 2026 *
-2.7x
P/E 2027 * -3.38x
Enterprise Value 65Cr 6.76Cr 5.92Cr 5.45Cr 5.06Cr 9.61Cr 644.42Cr 9.74Cr 25Cr 316.32Cr 25Cr 25Cr 1.1TCr EV / Sales 2026 *
25.1x
EV / Sales 2027 * 26.2x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day+0.41%
1 week-0.20%
Current month+1.46%
1 month+28.29%
3 months+9.44%
6 months-31.89%
Current year-19.10%
1 week 23
Extreme 23
25.35
1 month 18.62
Extreme 18.62
25.45
Current year 17.52
Extreme 17.52
36
1 year 17.5
Extreme 17.5
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Date Insider Type Main position Quantity % Market Cap.
04/25/04Buy

Chief Executive Officer

6 0.0000%
04/25/04Free

Chief Executive Officer

1,393 0.0040%
03/25/03Buy 1 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%-0.20%+21.14%+59.57% 8.78Cr
-2.15%-2.01%+56.65%+13.45% 32TCr
-1.96%-2.46%+28.36%-3.22% 7.24TCr
+1.67%+4.66%+49.59%+120.65% 942.38Cr
-1.11%+4.70%+8.17%+3.20% 864.53Cr
-5.79%+6.58%+18.45%+30.79% 451.87Cr
-2.55%-7.79%-8.10%+8.11% 441.04Cr
-1.14%-5.69%-34.65%+26.00% 343.1Cr
-1.69%+0.94%+47.72%+59.97% 278.88Cr
+1.66%+1.88%+17.18%-19.63% 218.78Cr
Average -1.40%+2.00%+20.45%+29.89% 4.28TCr
Weighted average by Cap. -2.05%+2.38%+48.66%+13.15%

Financials

2026 *2027 *
Net sales 2.6Cr 26.93L 23.58L 21.72L 20.16L 38.29L 26Cr 38.8L 1.01Cr 13Cr 1.01Cr 98.9L 44Cr 2.7Cr 27.96L 24.49L 22.56L 20.94L 39.76L 27Cr 40.3L 1.05Cr 13Cr 1.05Cr 1.03Cr 45Cr
Net income -32Cr -3.33Cr -2.92Cr -2.69Cr -2.5Cr -4.74Cr -318.09Cr -4.81Cr -13Cr -156.14Cr -13Cr -12Cr -541.35Cr -26Cr -2.68Cr -2.35Cr -2.16Cr -2.01Cr -3.81Cr -255.85Cr -3.87Cr -10Cr -125.59Cr -10Cr -9.85Cr -435.43Cr
Net Debt -20Cr -2.05Cr -1.8Cr -1.65Cr -1.54Cr -2.92Cr -195.6Cr -2.96Cr -7.71Cr -96Cr -7.7Cr -7.53Cr -332.88Cr -14Cr -1.47Cr -1.29Cr -1.19Cr -1.1Cr -2.09Cr -140.28Cr -2.12Cr -5.53Cr -69Cr -5.52Cr -5.4Cr -238.73Cr
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
65
Date Price Change Volume
06/26/06 SEK 24.35 +0.41% 11,326
03/26/03 SEK 24.25 -0.21% 12,759
02/26/02 SEK 24.30 +2.97% 18,971
01/26/01 SEK 23.60 -1.67% 13,849
30/26/30 SEK 24.00 -1.64% 28,864
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise